STOCK TITAN

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

Rhea-AI Summary
Quest Diagnostics employee Marissa McGhee receives praise for her exceptional patient care during a life insurance paramedical exam in Stamford, Connecticut. The patient commended Marissa for her customer-first approach and attentiveness during the exam, highlighting her professionalism and ability to handle a potentially concerning situation with ease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics, in collaboration with the University of Florida and Mount Sinai Medical Center, has developed a blood test that can potentially reduce the need for PET imaging in patients with mild cognitive impairment, aiding in the diagnosis of non-Alzheimer's disease causes and cutting healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
News
Rhea-AI Summary
Quest Diagnostics experiences positive growth and transformation as highlighted in a recent press release. The company is thriving in various aspects, showcasing strong financial performance and strategic business decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary
Quest Diagnostics (DGX) to announce first quarter 2024 financial results on April 23, 2024, with a conference call scheduled at 8:30 a.m. Eastern Time. Participants can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
earnings
-
Rhea-AI Summary
Donna Grant-Rudolph, a Patient Services Representative at Quest Diagnostics, has been recognized for her exceptional care and professionalism by patients and colleagues. Her dedication to patient comfort and well-being exemplifies Quest's values. This positive recognition highlights the company's commitment to customer service and employee development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics receives high praise from a patient for exceptional service at a Patient Service Center in Southern California. The patient commends Sandra Reyes for her professionalism and skill in drawing blood, highlighting her gentle approach and efficiency. The positive feedback underscores Quest's commitment to customer service and employee excellence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
News
Rhea-AI Summary
Quest Diagnostics (DGX) employee shares their journey to the company, highlighting the impact of a chance encounter on their career.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (NYSE:DGX) launches a groundbreaking consumer-initiated blood test for PFAS chemicals, offering consultation with a physician. The test targets individuals at risk of elevated PFAS exposure, as identified by National Academies of Sciences, Engineering, and Medicine. Organizations can also utilize the test for workforce, community, and research population screening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics collaborates with Western University to offer no-cost diagnostic testing for rare autoimmune diseases, leading to potentially life-saving diagnoses. The Biopsies Save Lives program under the Quest for Health Equity initiative has helped 3 patients so far, breaking down financial barriers and providing critical support to underserved communities in Southern California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
Rhea-AI Summary
Quest Diagnostics (NYSE:DGX) has been recognized as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. The company scored high in people management, use of corporate assets, and social responsibility, standing out in the 'Health Care: Pharmacy and Other Services' industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

DGX Stock Data

14.74B
109.71M
0.86%
92.03%
2.39%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator